INC spells out its IPO plans; Mid-sized CROs need to innovate to compete, CEO says;

> INC Research has set terms for its planned $150 million IPO, expecting to sell 8.1 million shares at a range of $17 to $20 each. News

> As mid-sized CROs struggle to compete with their larger rivals, success increasingly depends on innovative business models, Mike Jagielski, CEO of KCR, tells Outsourcing-Pharma. More

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.